Lee JL, et al. - Authors assessed if, in patients with inflammatory arthritis, the risk of cardiovascular events (CVEs) correlated to the treatment with anti-tumor necrosis factor (TNF) therapy vs other biologics or non-biologic therapy. They also compared the CVE risk between participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Consecutive participants in the Australian Rheumatology Association Database with RA, PsA and AS from September 2001 to January 2015 were included. Findings suggest current biologic use is linked to a decrease in major CVEs. In those who stopped biologic therapy, experts did not note any reduction in CVE risk. CVE risk, after adjustment, showed no significant difference between RA, AS or PsA.